PTC Therapeutics
PTCT
129 hedge funds and large institutions have $715M invested in PTC Therapeutics in 2017 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 53 increasing their positions, 32 reducing their positions, and 13 closing their positions.
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
66% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 32
16% more capital invested
Capital invested by funds: $615M → $715M (+$101M)
13% more funds holding
Funds holding: 114 → 129 (+15)
5.05% more ownership
Funds ownership: 81.32% → 86.37% (+5.1%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
52% less call options, than puts
Call options by funds: $41.2M | Put options by funds: $86.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$23.4M |
| 2 |
DAM
DLD Asset Management
New York
|
+$12M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.1M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$9.22M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$20.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$15.7M |
| 3 |
Morgan Stanley
New York
|
-$9.26M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$9.16M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$8.81M |
PTCT Hedge Fund Activity: Q3 2017 in Review
129 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2017, worth a combined $715M — up 16% from $615M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PTCT positions and 13 closed out — a net gain of 16 holders — while 53 added to existing stakes and 32 trimmed.
The largest buyer was Scopia Capital Management, opening a new position worth an estimated $23.4M. The largest seller was Frontier Capital Management, cutting an estimated $20.8M.
- 129 institutional investors held PTC Therapeutics (PTCT) as of Q3 2017, up from 114 in Q2 2017.
- Funds reported $715M of PTC Therapeutics stock for Q3 2017, up 16% quarter-over-quarter.
- 29 funds opened new PTC Therapeutics positions in Q3 2017 and 13 closed out, a net change of +16 holders.
- The largest PTC Therapeutics buyer in Q3 2017 was Scopia Capital Management, an estimated $23.4M added.
- The largest PTC Therapeutics seller in Q3 2017 was Frontier Capital Management, an estimated $20.8M sold.
Based on aggregated 13F filings for Q3 2017.